All In Biotech

Drug Trial Radar · NCT07221344

Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies

A Phase 1/2a Placebo-controlled Dose-escalating Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Trial to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia, as well as primary tauopathies, including microtubule associated protein tau -related frontotemporal dementia (MAPT-FTD) and progressive supranuclear palsy- Richardson syndrome (PSP-RS).

Conditions

  • Alzheimer Disease
  • Tauopathies
  • Frontotemporal Dementia
  • Progressive Supranuclear Palsy

Interventions

  • ARO-MAPT-SCDrug

    • single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection

  • PlaceboDrug

    • calculated volume to match active treatment by SC administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs) Over TimeTime frame: Through End of Trial (EOT; up to a maximum of Day 375)

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site 3

    East York, Ontario, Canada · Recruiting

  • Research Site 2

    Toronto, Ontario, Canada · Recruiting

  • Research Site 4

    Montreal, Quebec, Canada · Recruiting

  • Research Site 1

    Grafton, Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.